Holdings
Aisling Capital Management LP
As of Jun 30, 2026, Aisling Capital Management LP reported 12 positions worth US$447M. Largest: Bridgebio Pharma, Inc., Monte Rosa Therapeutics, Inc. and Syndax Pharmaceuticals, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Bridgebio Pharma, Inc. | 4.59M | US$342M | −500K | Jun 30, 2026 |
| Monte Rosa Therapeutics, Inc. | 1.56M | US$37.6M | no change | Jun 30, 2026 |
| Syndax Pharmaceuticals, Inc. | 1.32M | US$28.8M | no change | Jun 30, 2026 |
| Bicara Therapeutics Inc. | 569K | US$16.9M | no change | Jun 30, 2026 |
| Bridgebio Oncology Therapeutics, Inc. | 1.02M | US$7.76M | no change | Jun 30, 2026 |
| Scholar Rock Holding Corporation | 77,031 | US$4.24M | no change | Jun 30, 2026 |
| Biomea Fusion, Inc. | 2.05M | US$3.01M | no change | Jun 30, 2026 |
| Aclaris Therapeutics, Inc. | 434K | US$2.3M | no change | Jun 30, 2026 |
| Eupraxia Pharmaceuticals, Inc. | 325K | US$2.15M | no change | Jun 30, 2026 |
| Vtv Therapeutics Inc. | 50,000 | US$1.88M | new | Jun 30, 2026 |